Annual SG&A
$1.14 B
+$191.90 M+20.31%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual selling, general & administrative expenses is currently $1.14 billion, with the most recent change of +$191.90 million (+20.31%) on 31 December 2023. During the last 3 years, it has risen by +$366.10 million (+47.51%). VRTX annual SG&A is now at all-time high.VRTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$371.80 M
-$400.00 K-0.11%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly selling, general & administrative expenses is currently $371.80 million, with the most recent change of -$400.00 thousand (-0.11%) on 30 September 2024. Over the past year, it has increased by +$108.00 million (+40.94%). VRTX quarterly SG&A is now -0.11% below its all-time high of $372.20 million, reached on 30 June 2024.VRTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$37.73 B
-$479.80 M-1.26%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM selling, general & administrative expenses is currently $37.73 billion, with the most recent change of -$479.80 million (-1.26%) on 30 September 2024. Over the past year, it has increased by +$36.69 billion (+3545.43%). VRTX TTM SG&A is now -2.51% below its all-time high of $1.46 billion, reached on 30 September 2024.VRTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.3% | +40.9% | +3545.4% |
| 3 y3 years | +47.5% | +87.6% | +4634.8% |
| 5 y5 years | +103.8% | +132.8% | +6020.2% |
VRTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +47.5% | -0.1% | +87.6% | -2.5% | +491.3% |
| 5 y | 5 years | at high | +103.8% | -0.1% | +132.8% | -2.5% | +453.2% |
| alltime | all time | at high | >+9999.0% | -0.1% | +9522.2% | -2.5% | +275.9% |
Vertex Pharmaceuticals Incorporated Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $371.80 M(-0.1%) | $1.46 B(+8.0%) |
| June 2024 | - | $372.20 M(+8.6%) | $1.35 B(+8.9%) |
| Mar 2024 | - | $342.70 M(-7.2%) | $1.24 B(+8.9%) |
| Dec 2023 | $1.14 B(+20.3%) | $369.10 M(+39.9%) | $1.14 B(+9.8%) |
| Sept 2023 | - | $263.80 M(+0.5%) | $1.03 B(+1.7%) |
| June 2023 | - | $262.60 M(+8.9%) | $1.02 B(+4.9%) |
| Mar 2023 | - | $241.10 M(-9.8%) | $970.60 M(+2.7%) |
| Dec 2022 | $944.70 M(+12.5%) | $267.40 M(+8.3%) | $944.70 M(+1.3%) |
| Sept 2022 | - | $246.80 M(+14.6%) | $932.50 M(+5.5%) |
| June 2022 | - | $215.30 M(+0.0%) | $883.90 M(+2.4%) |
| Mar 2022 | - | $215.20 M(-15.7%) | $863.20 M(+2.7%) |
| Dec 2021 | $840.10 M(+9.0%) | $255.20 M(+28.8%) | $840.10 M(+5.4%) |
| Sept 2021 | - | $198.20 M(+1.8%) | $796.79 M(+1.7%) |
| June 2021 | - | $194.60 M(+1.3%) | $783.14 M(+0.4%) |
| Mar 2021 | - | $192.10 M(-9.3%) | $780.34 M(+1.3%) |
| Dec 2020 | $770.50 M(+17.0%) | $211.89 M(+14.8%) | $770.50 M(+2.2%) |
| Sept 2020 | - | $184.55 M(-3.8%) | $753.89 M(+3.4%) |
| June 2020 | - | $191.80 M(+5.2%) | $729.01 M(+5.1%) |
| Mar 2020 | - | $182.26 M(-6.7%) | $693.71 M(+5.3%) |
| Dec 2019 | $658.50 M(+18.1%) | $195.28 M(+22.3%) | $658.50 M(+6.8%) |
| Sept 2019 | - | $159.67 M(+2.0%) | $616.43 M(+3.8%) |
| June 2019 | - | $156.50 M(+6.4%) | $594.05 M(+3.3%) |
| Mar 2019 | - | $147.04 M(-4.0%) | $574.85 M(+3.1%) |
| Dec 2018 | $557.62 M(+12.4%) | $153.21 M(+11.6%) | $557.62 M(+3.4%) |
| Sept 2018 | - | $137.29 M(-0.0%) | $539.20 M(+3.2%) |
| June 2018 | - | $137.30 M(+5.8%) | $522.62 M(+2.0%) |
| Mar 2018 | - | $129.81 M(-3.7%) | $512.56 M(+3.3%) |
| Dec 2017 | $496.08 M(+14.6%) | $134.79 M(+11.7%) | $496.08 M(+5.3%) |
| Sept 2017 | - | $120.71 M(-5.1%) | $471.19 M(+3.2%) |
| June 2017 | - | $127.25 M(+12.3%) | $456.54 M(+3.5%) |
| Mar 2017 | - | $113.33 M(+3.1%) | $440.94 M(+1.9%) |
| Dec 2016 | $432.83 M(+14.9%) | $109.91 M(+3.6%) | $432.83 M(+3.2%) |
| Sept 2016 | - | $106.06 M(-5.0%) | $419.47 M(+1.5%) |
| June 2016 | - | $111.65 M(+6.1%) | $413.19 M(+4.4%) |
| Mar 2016 | - | $105.21 M(+9.0%) | $395.93 M(+5.1%) |
| Dec 2015 | $376.57 M(+23.3%) | $96.55 M(-3.2%) | $376.57 M(+5.0%) |
| Sept 2015 | - | $99.77 M(+5.7%) | $358.55 M(+7.3%) |
| June 2015 | - | $94.39 M(+9.9%) | $334.00 M(+5.3%) |
| Mar 2015 | - | $85.86 M(+9.3%) | $317.06 M(+3.8%) |
| Dec 2014 | $305.41 M(-14.3%) | $78.53 M(+4.4%) | $305.41 M(+1.8%) |
| Sept 2014 | - | $75.22 M(-2.9%) | $299.94 M(-3.6%) |
| June 2014 | - | $77.45 M(+4.4%) | $311.14 M(-8.5%) |
| Mar 2014 | - | $74.21 M(+1.6%) | $340.21 M(-5.2%) |
| Dec 2013 | $356.19 M(-17.7%) | $73.06 M(-15.5%) | $358.88 M(-8.5%) |
| Sept 2013 | - | $86.43 M(-18.9%) | $392.16 M(-2.8%) |
| June 2013 | - | $106.52 M(+14.7%) | $403.42 M(-2.7%) |
| Mar 2013 | - | $92.88 M(-12.7%) | $414.41 M(-4.2%) |
| Dec 2012 | $432.68 M(+8.0%) | $106.34 M(+8.9%) | $432.68 M(-3.5%) |
| Sept 2012 | - | $97.68 M(-16.9%) | $448.23 M(-2.8%) |
| June 2012 | - | $117.51 M(+5.7%) | $461.19 M(+4.7%) |
| Mar 2012 | - | $111.15 M(-8.8%) | $440.34 M(+9.9%) |
| Dec 2011 | $400.72 M(+113.4%) | $121.88 M(+10.1%) | $400.72 M(+17.4%) |
| Sept 2011 | - | $110.65 M(+14.5%) | $341.32 M(+22.1%) |
| June 2011 | - | $96.66 M(+35.1%) | $279.52 M(+24.9%) |
| Mar 2011 | - | $71.52 M(+14.5%) | $223.77 M(+19.2%) |
| Dec 2010 | $187.80 M(+44.2%) | $62.48 M(+27.9%) | $187.80 M(+18.9%) |
| Sept 2010 | - | $48.85 M(+19.4%) | $157.90 M(+8.4%) |
| June 2010 | - | $40.91 M(+15.1%) | $145.61 M(+6.1%) |
| Mar 2010 | - | $35.55 M(+9.1%) | $137.22 M(+5.4%) |
| Dec 2009 | $130.19 M(+28.5%) | $32.57 M(-10.9%) | $130.19 M(+7.4%) |
| Sept 2009 | - | $36.57 M(+12.4%) | $121.21 M(+8.4%) |
| June 2009 | - | $32.53 M(+14.0%) | $111.82 M(+3.4%) |
| Mar 2009 | - | $28.52 M(+20.9%) | $108.19 M(+6.8%) |
| Dec 2008 | $101.29 M(+19.5%) | $23.59 M(-13.2%) | $101.29 M(+0.1%) |
| Sept 2008 | - | $27.19 M(-5.9%) | $101.15 M(+6.1%) |
| June 2008 | - | $28.89 M(+33.6%) | $95.38 M(+6.2%) |
| Mar 2008 | - | $21.62 M(-7.8%) | $89.81 M(+6.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2007 | $84.73 M(+46.4%) | $23.45 M(+9.5%) | $84.73 M(+9.9%) |
| Sept 2007 | - | $21.42 M(-8.2%) | $77.11 M(+9.4%) |
| June 2007 | - | $23.32 M(+41.0%) | $70.47 M(+14.6%) |
| Mar 2007 | - | $16.54 M(+4.4%) | $61.52 M(+6.3%) |
| Dec 2006 | $57.86 M(+31.5%) | $15.84 M(+7.2%) | $57.86 M(+5.5%) |
| Sept 2006 | - | $14.77 M(+2.8%) | $54.83 M(+7.9%) |
| June 2006 | - | $14.37 M(+11.6%) | $50.80 M(+7.5%) |
| Mar 2006 | - | $12.88 M(+0.5%) | $47.24 M(+7.4%) |
| Dec 2005 | $43.99 M(+4.4%) | $12.81 M(+19.3%) | $43.99 M(+2.7%) |
| Sept 2005 | - | $10.74 M(-0.7%) | $42.84 M(+0.3%) |
| June 2005 | - | $10.81 M(+12.3%) | $42.70 M(+1.6%) |
| Mar 2005 | - | $9.63 M(-17.4%) | $42.04 M(-0.2%) |
| Dec 2004 | $42.14 M(+7.8%) | $11.66 M(+10.0%) | $42.14 M(+2.9%) |
| Sept 2004 | - | $10.60 M(+4.3%) | $40.96 M(+2.9%) |
| June 2004 | - | $10.16 M(+4.5%) | $39.79 M(-0.1%) |
| Mar 2004 | - | $9.72 M(-7.2%) | $39.83 M(-4.2%) |
| Dec 2003 | $39.08 M(-4.8%) | $10.47 M(+11.0%) | $41.56 M(+19.5%) |
| Sept 2003 | - | $9.44 M(-7.5%) | $34.77 M(-9.1%) |
| June 2003 | - | $10.20 M(-10.9%) | $38.27 M(-7.6%) |
| Mar 2003 | - | $11.45 M(+210.8%) | $41.41 M(+0.9%) |
| Dec 2002 | $41.06 M(+28.9%) | $3.69 M(-71.5%) | $41.06 M(+22.8%) |
| Sept 2002 | - | $12.93 M(-3.1%) | $33.42 M(+4.1%) |
| June 2002 | - | $13.35 M(+20.3%) | $32.12 M(+11.0%) |
| Mar 2002 | - | $11.10 M(-381.2%) | $28.95 M(+14.2%) |
| Dec 2001 | $31.86 M(-23.0%) | -$3.95 M(-134.0%) | $25.35 M(-50.1%) |
| Sept 2001 | - | $11.62 M(+14.2%) | $50.84 M(+11.1%) |
| June 2001 | - | $10.18 M(+35.8%) | $45.76 M(+8.3%) |
| Mar 2001 | - | $7.50 M(-65.2%) | $42.24 M(+2.2%) |
| Dec 2000 | $41.35 M(+58.4%) | $21.55 M(+229.3%) | $41.32 M(+46.6%) |
| Sept 2000 | - | $6.54 M(-1.7%) | $28.18 M(+0.5%) |
| June 2000 | - | $6.66 M(+1.2%) | $28.04 M(+4.4%) |
| Mar 2000 | - | $6.58 M(-21.7%) | $26.84 M(+3.0%) |
| Dec 1999 | $26.10 M(+44.2%) | $8.40 M(+31.3%) | $26.07 M(+10.6%) |
| Sept 1999 | - | $6.40 M(+17.1%) | $23.57 M(+7.3%) |
| June 1999 | - | $5.47 M(-5.8%) | $21.97 M(+6.1%) |
| Mar 1999 | - | $5.80 M(-1.7%) | $20.70 M(+13.7%) |
| Dec 1998 | $18.10 M(+58.8%) | $5.90 M(+22.9%) | $18.20 M(+13.8%) |
| Sept 1998 | - | $4.80 M(+14.3%) | $16.00 M(+14.3%) |
| June 1998 | - | $4.20 M(+27.3%) | $14.00 M(+12.9%) |
| Mar 1998 | - | $3.30 M(-10.8%) | $12.40 M(+9.7%) |
| Dec 1997 | $11.40 M(-50.2%) | $3.70 M(+32.1%) | $11.30 M(-54.8%) |
| Sept 1997 | - | $2.80 M(+7.7%) | $25.00 M(+4.2%) |
| June 1997 | - | $2.60 M(+18.2%) | $24.00 M(+3.0%) |
| Mar 1997 | - | $2.20 M(-87.4%) | $23.30 M(+1.7%) |
| Dec 1996 | $22.90 M(+222.5%) | $17.40 M(+866.7%) | $22.90 M(+201.3%) |
| Sept 1996 | - | $1.80 M(-5.3%) | $7.60 M(+1.3%) |
| June 1996 | - | $1.90 M(+5.6%) | $7.50 M(+2.7%) |
| Mar 1996 | - | $1.80 M(-14.3%) | $7.30 M(+2.8%) |
| Dec 1995 | $7.10 M(-82.4%) | $2.10 M(+23.5%) | $7.10 M(-55.9%) |
| Sept 1995 | - | $1.70 M(0.0%) | $16.10 M(-34.8%) |
| June 1995 | - | $1.70 M(+6.3%) | $24.70 M(-25.6%) |
| Mar 1995 | - | $1.60 M(-85.6%) | $33.20 M(-17.8%) |
| Dec 1994 | $40.30 M(+50.9%) | $11.10 M(+7.8%) | $40.40 M(+4.4%) |
| Sept 1994 | - | $10.30 M(+1.0%) | $38.70 M(+8.4%) |
| June 1994 | - | $10.20 M(+15.9%) | $35.70 M(+14.8%) |
| Mar 1994 | - | $8.80 M(-6.4%) | $31.10 M(+16.5%) |
| Dec 1993 | $26.70 M(+93.5%) | $9.40 M(+28.8%) | $26.70 M(+25.9%) |
| Sept 1993 | - | $7.30 M(+30.4%) | $21.20 M(+21.1%) |
| June 1993 | - | $5.60 M(+27.3%) | $17.50 M(+40.0%) |
| Mar 1993 | - | $4.40 M(+12.8%) | $12.50 M(+12.6%) |
| Dec 1992 | $13.80 M(+56.8%) | $3.90 M(+8.3%) | $11.10 M(+14.4%) |
| Sept 1992 | - | $3.60 M(+500.0%) | $9.70 M(+16.9%) |
| June 1992 | - | $600.00 K(-80.0%) | $8.30 M(-15.3%) |
| Mar 1992 | - | $3.00 M(+20.0%) | $9.80 M(+44.1%) |
| Dec 1991 | $8.80 M(+37.5%) | $2.50 M(+13.6%) | $6.80 M(+58.1%) |
| Sept 1991 | - | $2.20 M(+4.8%) | $4.30 M(+104.8%) |
| June 1991 | - | $2.10 M | $2.10 M |
| Dec 1990 | $6.40 M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual SG&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM SG&A year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual selling, general & administrative expenses?
The current annual SG&A of VRTX is $1.14 B
What is the all time high annual SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual selling, general & administrative expenses is $1.14 B
What is Vertex Pharmaceuticals Incorporated annual SG&A year-on-year change?
Over the past year, VRTX annual selling, general & administrative expenses has changed by +$191.90 M (+20.31%)
What is Vertex Pharmaceuticals Incorporated quarterly selling, general & administrative expenses?
The current quarterly SG&A of VRTX is $371.80 M
What is the all time high quarterly SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly selling, general & administrative expenses is $372.20 M
What is Vertex Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
Over the past year, VRTX quarterly selling, general & administrative expenses has changed by +$108.00 M (+40.94%)
What is Vertex Pharmaceuticals Incorporated TTM selling, general & administrative expenses?
The current TTM SG&A of VRTX is $37.73 B
What is the all time high TTM SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM selling, general & administrative expenses is $1.46 B
What is Vertex Pharmaceuticals Incorporated TTM SG&A year-on-year change?
Over the past year, VRTX TTM selling, general & administrative expenses has changed by +$36.69 B (+3545.43%)